I-Mab Announces Upcoming Participation at January Conferences


    SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in January 2022. Details of the conferences and management presentation are as follows:

    40th Annual J.P. Morgan Healthcare Conference

    Presentation: Tuesday, January 11, 2022, at 4:30 p.m. E.S.T.

    Presenter: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director

    Webcast link: https://jpmorgan.metameetings.net/events/healthcare22/sessions/40371-i-mab-biopharma/webcast?gpu_only=true&kiosk=true  The webcast will also be available under "Event Calendar" on IMAB's IR website at http://ir.i-mabbiopharma.com/ .

    One-on-one and small group meetings: January 19-21, 2022

    Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

    For more information, please contact your J.P. Morgan representative.

    Morgan Stanley Virtual China New Economy Summit 2022

    One-on-one and small group meetings: January 5-7, 2022

    Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

    For more information, please contact your Morgan Stanley representative.

    H.C. Wainwright Virtual BioConnect Conference

    One-on-one and small group meetings: January 10 - 13, 2021

    Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

    For more information, please contact your H.C.Wainwright representative.

    UBS Greater China Conference 2022

    One-on-one and small group meetings: January 11-14, 2022

    Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

    For more information, please contact your UBS representative.

    About I-Mab

    I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedInTwitter, and WeChat.

    For more information, please contact:

    I-Mab Contacts

    John Long
    Chief Financial Officer

    john.long@i-mabbiopharma.com

    +86 21 6057 8000

     

    Gigi Feng
    Chief Communications Officer

    gigi.feng@i-mabbiopharma.com

    +86 21 6057 5709

     

    Investor Inquiries:

    The Piacente Group, Inc.
    Emilie Wu
    E-mail: emilie@thepiacentegroup.com
    Office line: + 86 21 6039 8363

    PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content – from rich media to online video to multimedia – and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world's largest multi-channel distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a Cision company.

    RELATED NEWS